C-Path Welcomes Red Nucleus Clinical C-Path is proud to welcome Red Nucleus Clinical as the newest member of its Electronic Clinical Outcome Assessment (eCOA) Consor
C-Path’s CDRC Meeting Highlights the Importance of Drug Repurposing The Critical Path Institute’s CURE Drug Repurposing Collaboratory and FDA hosted their annual meeting April 18-20 to bring toget
Rare Disease COA Consortium Announces Publication of Open Access Article C-Path’s Rare Disease COA Consortium is pleased to announce that “Approaches to the Assessment of Clinical Benefit of Treatmen
March 29, 2023 C-Path Appoints Key Scientific Leaders to Executive Roles Critical Path Institute (C-Path) announced today the appointment of three accomplished leaders to key executive roles within the..
March 15, 2023 Evaluation of Novel Urinary Biomarkers in Beagle Dogs With Amphotericin B-Induced Kidney Injury
C-Path Welcomes TransPerfect Life Sciences C-Path is proud to welcome TransPerfect Life Sciences as the newest member of its Electronic Clinical Outcome Asse
C-Path Stands with Bruce Willis, Neurodegenerative Disease Community After FTD Diagnosis C-Path and its members stand with Bruce Willis and his family as they bravely revealed the difficult news of his Frontotemporal De
Regulus Therapeutics Joins PKDOC C-Path is excited to announce that Regulus Therapeutics, Inc. has joined the Polycystic Kidney Disease Outcomes Consortium (PKD
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) Joins PKDOC C-Path is excited to announce that Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) has joined its Polycy
C-Path and Mobilise-D Collaborate to Improve Impact on the Organizations’ Common Goals Critical Path Institute is pleased to announce the recent collaboration agreement between C-Path and Mobilise-D. By
